Aromatase inhibitor-induced arthralgia in early breast cancer: What do we know and how can we find out more?

Breast Cancer Research and Treatment

Volumn 120, Issue 3, 2010, Pages 525-538

  Din, Omar S ^a   Dodwell, David ^b   Wakefield, Richard J ^c   Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c CHAPEL ALLERTON HOSPITAL   (United Kingdom)

Author keywords

Aromatase inhibitors; Arthralgia; Breast cancer; Imaging; Review

Indexed keywords

ALKALINE PHOSPHATASE; ANASTROZOLE; AROMATASE INHIBITOR; C REACTIVE PROTEIN; CALCIUM; COLECALCIFEROL; CREATINE KINASE; ESTROGEN; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN; VITAMIN D;

AGE DISTRIBUTION; ARTHRALGIA; ARTHRITIS; AUTOIMMUNITY; BONE DENSITY; BONE PAIN; BREAST CANCER; BURSITIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CARPAL TUNNEL SYNDROME; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG POTENCY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DUAL ENERGY X RAY ABSORPTIOMETRY; ELECTROMYOGRAPHY; ERYTHROCYTE SEDIMENTATION RATE; ESTROGEN BLOOD LEVEL; FATIGUE; FRACTURE; GEOGRAPHIC DISTRIBUTION; GRIP STRENGTH; HOT FLUSH; HUMAN; JOINT STIFFNESS; MENOPAUSE; MORNING STIFFNESS; MUSCULOSKELETAL DISEASE; MUSCULOSKELETAL PAIN; MYALGIA; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOARTHRITIS; PATHOGENESIS; PHARMACOGENOMICS; PREVALENCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; SYNOVITIS; TENDINITIS; TREATMENT INDICATION; VISUAL ANALOG SCALE; VITAMIN SUPPLEMENTATION;

ADENOCARCINOMA; AGED; ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; ARTHRALGIA; AUTOIMMUNITY; BREAST NEOPLASMS; CARPAL TUNNEL SYNDROME; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS, PHASE III AS TOPIC; CYTOKINES; DIAGNOSTIC IMAGING; EDEMA; ESTROGENS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASMS, HORMONE-DEPENDENT; POSTMENOPAUSE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RATS;

EID: 77950865581     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0757-7     Document Type: Review

References (96)

1. EBCTCG (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365(9472): 1687-1717 (Pubitemid 40719106)
2. Bonneterre J et al (2000) Anastrozole versus tamoxifen as firstline therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18(22): 3748-3757
3. Mouridsen H et al (2003) Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21(11): 2101-2109
4. Nabholtz JM et al (2000) Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 18(22): 3758-3767
5. Howell A et al (2005) Results of the ATAC (arimldex, tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365(9453): 60-62 (Pubitemid 40082147)
6. Goss PE et al (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349(19): 1793-1802 (Pubitemid 37362955)
7. Coombes RC et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11): 1081-1092
8. Coombes RC et al (2007) Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 369(9561): 559-570
9. Jakesz R et al (2005) Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 366(9484): 455-462 (Pubitemid 41111693)
10. Thurlimann B et al (2005) A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 353(26): 2747-2757 (Pubitemid 43016814)
11. Boccardo F et al (2006) Switching to anastrozole versus continued tamoxifen treatment of early breast cancer. Updated results of the Italian tamoxifen anastrozole (ITA) trial. Ann Oncol 17(7): vii10-4
12. Yager JD, Davidson NE (2006) Estrogen carcinogenesis in breast cancer. N Engl J Med 354(3): 270-282
13. Njar VC, Brodie AM (1999) Comprehensive pharmacology and clinical efficacy of aromatase inhibitors. Drugs 58(2): 233-255 (Pubitemid 29403265)
14. Campos SM (2004) Aromatase inhibitors for breast cancer in postmenopausal women, Oncologist 9(2): 126-136 (Pubitemid 38452112)
15. di Salle E et al (1992) Exemestane (FCE 24304), a new steroidal aromatase inhibitor. J Steroid Biochem Mol Biol 43(1-3):137-143
16. Greendale GA, Lee NP, Arriola ER (1999) The menopause. Lancet 353(9152): 571-580
17. Cecil RL, Archer BH (1925) Arthritis of the menopause. JAMA 84: 75-79
18. Avis N et al (2004) Baillere's clinical endocrinology and metabolism. In: Burger H (ed) The evolution of menopausal symptoms. Bailliere Tindall, London
19. Dugan SA et al (2006) Musculoskeletal pain and menopausal status. Clin J Pain 22(4): 325-331
20. XuJetal(2005)Naturalhistoryofmenopausesymptomsinprimarycarepatients: aMetroNetstudy.JAmBoardFamPract18(5):374-382(Pubitemid41663981)
21. Szoeke CE et al (2008) The relationship of reports of aches and joint pains to the menopausal transition: a longitudinal study. Climacteric 11(1): 55-62
22. HuangCetal(1997)Factorsassociatedwithjointpainamongpostmenopausalwomen. IntJObesRelatMetabDisord21(5):349-354(Pubitemid27190185)
23. Dowsett M, Lonning PE (1997) Anastrozole-a new generation in aromatase inhibition: clinical pharmacology. Oncology 54(Suppl 2): 11-14
24. Nielsen RH et al (2008) Oestrogen exhibits type II collagen protective effects and attenuates collagen-induced arthritis in rats. Clin Exp Immunol 152(1): 21-27
25. Cvoro A et al (2008) Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. J Immunol 180(1): 630-636
26. Dawson-Basoa M, Gintzler AR (1997) Involvement of spinal cord delta opiate receptors in the antinociception of gestation and its hormonal simulation. Brain Res 757(1): 37-42 (Pubitemid 27244619)
27. Riley JL 3rd et al (1999) A meta-analytic review of pain perception across the menstrual cycle. Pain 81(3): 225-235
28. Dietrich W et al (2006) Estrogen receptor-beta is the predominant estrogen receptor subtype in normal human synovia. J Soc Gynecol Investig 13(7):512-517 (Pubitemid 44528300)
29. Coleman RE et al (2008) Aromatase inhibitor-induced arthralgia: clinical experience and treatment recommendations. Cancer Treat Rev 34(3): 375-1282
30. Richette P, Corvol M, Bardin T (2003) Estrogens, cartilage, and osteoarthritis. Joint Bone Spine 70(4): 257-262
31. Sniekers YH et al (2008) Animal models for osteoarthritis: the effect of ovariectomy and estrogen treatment-a systematic approach. Osteoarthr Cartil 16(5): 533-541
32. Oestergaard S et al (2006) Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum 54(8): 2441-2451. (Pubitemid 44205004)
33. Nevitt MC et al (2001) The effect of estrogen plus progestin on knee symptoms and related disability in postmenopausal women: The Heart and Estrogen/Progestin Replacement Study, a randomized, double-blind, placebo-controlled trial. Arthritis Rheum 44(4): 811-818 (Pubitemid 32319773)
34. Le Bail J et al (2001) Aromatase in synovial cells from postmenopausal women. Steroids 66(10): 749-757 (Pubitemid 32755772)
35. Sasano H et al (1997) Aromatase in human bone tissue. J Bone Miner Res 12(9): 1416-1423
36. Toesca A et al (2008) Estrogen and progesterone receptors in carpal tunnel syndrome. Cell Biol Int 32(1): 75-79 (Pubitemid 351249141)
37. Morel B, Marotte H, Miossec P (2007) Will steroidal aromatase inhibitors induce rheumatoid arthritis? Ann Rheum Dis 66(4): 557-558
38. Laroche Metal (2007) Joint pain with aromatase inhibitors: abnormal frequency of Sjogren's syndrome. J Rheumatol 34 (11):2259- 2263(Pubitemid350076888)
39. Henry NL et al (2008) Prospective characterization of musculoskeletal symptoms in early stage breast cancer patients treated with aromatase inhibitors. Breast Cancer Res Treat 111(2): 365-372
40. Pfeilschifter J et al (2002) Changes in proinflammatory cytokine activity after menopause. Endocr Rev 23(1): 90-119 (Pubitemid 34185307)
41. Mao JJ et al (2009) Patterns and risk factors associated with aromatase inhibitor-related arthralgia among breast cancer survivors. Cancer 115(16): 3631-3639
42. Sestak I et al (2008) Risk factors for joint symptoms in patients enrolled in the ATAC trial: a retrospective, exploratory analysis. Lancet Oncol 9(9) : 866-872
43. Buzdar A (2006) Clinical features of joint symptoms observed in the 'Arimidex', Tamoxifen, Alone or in Combination (ATAC) trial. J Clin Oncol 24(18S): 551
44. Buzdar A et al (2006) Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol 7(8): 633-643
45. Fallowfield L et al (2004) Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22(21): 4261-4271 (Pubitemid 41185147)
46. Cella D et al (2006) Quality of life of postmenopausal women in the ATAC ("Arimidex", tamoxifen, alone or in combination) trial after completion of 5 years' adjuvant treatment for early breast cancer. Breast Cancer Res Treat 100(3): 273-284 (Pubitemid 44707921)
47. Khanduri S, Dodwell DJ (2007) Aromatase inhibitors and musculoskeletal symptoms. Breast 17(1): 76-79
48. Cuzick J et al (2008) Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial. Lancet Oncol 9(12): 1143-1148
49. Fallowfield L (2008) There's many a slip twixt cup and lip: adherence issues in cancer therapy. Nat Clin Pract Oncol 5(3): 118-119
50. Chlebowski RT, Geller ML (2006) Adherence to endocrine therapy for breast cancer. Oncology 71(1-2): 1-9
51. Fallowfield LJ et al (2006) Quality of life in the intergroup exemestane study: a randomized trial of exemestane versus continued tamoxifen after 2 to 3 years of tamoxifen in postmenopausal women with primary breast cancer, J Clin Oncol 24(6): 910-917 (Pubitemid 46638844)
52. Whelan TJ et al (2005) Assessment of quality of life in MA. 17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23(28): 6931-6940
53. Felson DT (2008) Comparing the prevalence of rheumatic diseases in China with the rest of the world. Arthritis Res Ther 10(1): 106
54. Crew KD et al (2007) Prevalence of joint symptoms in postmenopausal women taking aromatase inhibitors for early-stage breast cancer. J Clin Oncol 25(25): 3877-3883 (Pubitemid 47477264)
55. Presant CA et al (2007) Aromatase inhibitor-associated arthralgia and/or bone pain: frequency and characterization in non-clinical trial patients. Clin. Breast Cancer 7(10): 775-778
56. Dent SF et al (2007) Adjuvant aromatse inhibitors in early breast cancer-toxicity and adherence. Important observations in clinical practice. In: San Antonio breast cancer symposium. San Antonio, Texas
57. Renshaw L et al (2007) Comparison of joint problems as reported by patients in a randomised adjuvant trial of anastrozole and letrozole. In: San Antonio breast caner symposium, p 2072
58. Morales L et al (2007) Debilitating musculoskeletal pain and stiffness with letrozole and exemestane: associated tenosynovial changes on magnetic resonance imaging. Breast Cancer Res Treat 104(1): 87-91. (Pubitemid 46976635)
59. Morales L et al (2008) Prospective study to assess short-term intra-articular and tenosynovial changes in the aromatase inhibitor-associated arthralgia syndrome. J Clin Oncol 26(19): 3147-3152
60. Alegre-Sancho JJ et al (2008) Trigger thumb in patients with breast cancer and hand pain associated with aromatase inhibitors. Ann Rheum Dis 67(Suppl II)
61. Dizdar O et al (2009) Sonographic and electrodiagnostic evaluations in patients with aromatase inhibitor-related arthralgia. J Clin. Oncol 27(30): 4955-4960
62. Sestak I, Sapunar F, Cuzick J (2009) Aromatase inhibitor-induced carpal tunnel syndrome: results from the ATAC trial. J Clin Oncol 27(30): 4961-4965
63. Sestak I, Cuzick J (2007) Risk factors for joint symptoms in the ATAC trial. In: San Antonio breast caner symposium, p 2071
64. Singh S, Howell A, Cuzick J (2006) Vit D levels among patients with arthralgia: results from IBIS-II breast cancer prevention study. In: San Antonio breast caner symposium, p 1068
65. Azria D et al (2007) Letrozole induced arthralgia: results of a multicentric prospective trial exploring clinical parameters and plasma biomarkers. In: ASCO breast cancer symposium, p 228
66. Khan QJ et al (2010) Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119(1): 111-118
67. Mao JJ et al (2009) Feasibility trial of electroacupuncture for aromatase inhibitor-related arthralgia in breast cancer survivors. Integr Cancer Ther 8(2): 123-129
68. Crew KD et al (2009) Randomized, blinded, placebo-controlled trial of acupuncture for the management of aromatase inhibitorassociated joint symptoms in women with early-stage breast cancer. J Clin Oncol 27(15s): 571.
69. Basch E et al (2006) Patient versus clinician symptom reporting using the National Cancer Institute Common Terminology Criteria for Adverse Events: results of a questionnaire-based study. Lancet Oncol 7(11):903-909 (Pubitemid 44615944)
70. Hershman DL (2008) Getting a grip on aromatase inhibitorassociated arthralgias. J Clin Oncol 26(19): 3120-3121
71. Allen KD et al (2007) Validity and factor structure of the AUSCAN Osteoarthritis Hand Index in a community-based sample. Osteoarthr Cartil 15(7): 830-836
72. Sautner J et al (2004) Development of the M-SACRAH, a modified, shortened version of SACRAH (Score for the Assessment and Quantification of Chronic Rheumatoid Affections of the Hands). Rheumatology 43(11): 1409-1413 (Pubitemid 39480930)
73. Sautner J et al (2009) A comparison of the Modified Score for the Assessment of Chronic Rheumatoid Affections of the Hands and the Australian/Canadian Osteoarthritis Hand Index in Hand Osteoarthritis Patients. Int J Rheumatol 1-7
74. Harkonen R, Harju R, Alaranta H (1993) Accuracy of the Jamar dynamometer, J Hand Ther 6(4): 259-262
75. MathiowetzVetal(1984) Reliabilityandvalidityofgripandpinchstrengthevaluations.JHandSurgAm9(2): 222-226(Pubitemid14135263)
76. Backhaus M et al (2001) Guidelines for musculoskeletal ultrasound in rheumatology. Ann Rheum Dis 60(7): 641-649
77. Wakefield RJ et al (2005) Musculoskeletal ultrasound including definitions for ultrasonographic pathology. J Rheumatol 32(12): 2485-2487
78. Schmidt WA (2007) Technology insight: the role of color and power Doppler ultrasonography in rheumatology. Nat Clin Pract Rheumatol. 3(1): 35-42 (quiz 59)
79. Tan AL, Emery P (2008) Role of oestrogen in the development of joint symptoms? Lancet Oncol 9(9): 817-818
80. Tan AL et al (2003) Imaging of the musculoskeletal system: magnetic resonance imaging, ultrasonography and computed tomography. Best Pract Res Clin Rheumatol 17(3): 513-528
81. Haavardsholm EA et al (2007) Introduction of a novel magnetic resonance imaging tenosynovitis score for rheumatoid arthritis: reliability in a multireader longitudinal study. Ann Rheum Dis 66(9): 1216-1220 (Pubitemid 47309740)
82. Haavardsholm EA et al (2005) Reliability and sensitivity to change of the OMERACT rheumatoid arthritis magnetic resonance imaging score in a multireader, longitudinal setting. Arthritis Rheum 52(12): 3860-3867
83. Lester JE et al (2008) Prevention of anastrozole-induced bone loss with monthly oral ibandronate during adjuvant aromatase inhibitor therapy for breast cancer. Clin Cancer Res 14(19): 6336-6342
84. Brufsky A et al (2008) Integrated analysis of zoledronic acid for prevention of aromatase inhibitor-associated bone loss in postmenopausal women with early breast cancer receiving adjuvant letrozole. Oncologist 13(5): 503-514 (Pubitemid 351872868)
85. Ellis GK et al (2008) Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer. J Clin Oncol 26(30): 4875-4882
86. Haugeberg G et al (2006) Hand bone loss in early undifferentiated arthritis: evaluating bone mineral density loss before the development of rheumatoid arthritis. Ann Rheum Dis 65(6): 736-740 (Pubitemid 43799171)
87. Haugeberg G et al (2007) Hand bone densitometry: a more sensitive standard for the assessment of early bone damage in rheumatoid arthritis. Ann Rheum Dis 66(11): 1513-1517 (Pubitemid 350032662)
88. Henry NL et al (2008) A. distinct inflammatory marker pattern in patients with aromatase inhibitor (AI)-induced musculoskeletal symptoms. In: SABCS. San Antonio, Texas
89. Hunter DJ et al (2007) Cartilage markers and their association with cartilage loss on magnetic resonance imaging in knee osteoarthritis: the Boston Osteoarthritis Knee Study. Arthritis Res Ther 9(5): R108
90. Williams FM, Spector TD (2008) Biomarkers in osteoarthritis, Arthritis Res Ther 10(1): 101
91. Landewe R (2007) Predictive markers in rapidly progressing rheumatoid arthritis. J Rheumatol Suppl 80: 8-15
92. Wild N et al (2008) Diagnosis of rheumatoid arthritis: multivariate analysis of biomarkers, Biomarkers 13(1):88-105
93. Clinical Trials.gov 2009 7th July 2009]; Available from: http://clinicaltrials.gov/ct2/results?term=breast+cancer+AND+arthralgia
94. Jakesz R et al (2007) Extended adjuvant therapy with anastrozole among postmenopausal breast cancer patients: results from the randomized Austrian Breast and Colorectal Cancer Study Group Trial 6a. J Natl Cancer Inst 99(24): 1845-1853 (Pubitemid 351767193)
95. Burstein HJ (2007) Aromatase inhibitor-associated arthralgia syndrome. Breast 16(3): 223-234
96. Bianchi S et al. (2007) Ultrasound of the digital flexor system: normal and pathological findings. J Ultrasound 10: 85-92 (Pubitemid 47379599)